BSETYCHE INDUSTRIES LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 11 Aug, 2026 · 20:42 IST

Tyche Industries Q1 FY26 net loss; auditor flags qualified review

Qualified OpinionRevenue DeclinePat NegativeResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-14.3%Reaction day
₹125.60
prior close
₹120.85
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-14.6% vs market
Pharmaceuticals peers, median of 165sector-0.6%-13.7% vs sector

On the reaction day the stock moved 14.6 pts less than Nifty Microcap 250 and 13.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.8
10m
-7.1
15m
-6.1
30m
-8.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-14.3+0.4-14.6-0.6-13.7
Next day
-16.1+0.5-16.7-0.3-15.8
2d
-16.7+0.6-17.3-0.6-16.1
3d
-15.8+0.7-16.5-1.4-14.4
4d
-17.0+1.1-18.1-1.1-16.0
5d
-17.4+0.5-17.9-1.9-15.4
1w
-16.3+1.3-17.6-1.2-15.1
15d
-17.4+0.5-17.9-0.9-16.4
1m
-14.2-0.8-13.3-0.2-14.0
2m
-15.8-0.9-14.9-3.2-12.6
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tyche Industries posted a net loss of Rs 4.17 lakhs in Q1 FY26 versus a profit of Rs 243.15 lakhs in Q1 FY25. Revenue from operations fell about 28 percent YoY to Rs 909.93 lakhs. The statutory auditor issued a qualified review, noting sales of Rs 160.43 lakhs booked before control of goods passed to customers, not per Ind-AS 115, overstating turnover and net profit.

Likely market impact

Weak quarter with revenue decline, slip into loss, and auditor qualification. Negative near term signal for shareholders.